Endoscopic mucosal resection using cold snare versus hot snare in treatment for 10–19 mm non-pedunculated colorectal polyps: protocol of a non-inferiority randomised controlled study

医学 粘膜切除术 协议(科学) 外科 随机对照试验 内窥镜检查 普通外科 内科学 病理 替代医学
作者
Qingwei Jiang,Xiaxiao Yan,Duan Wang,Shengyu Zhang,Yuelun Zhang,Yunlu Feng,Aiming Yang,Dong Wu
出处
期刊:BMJ Open [BMJ]
卷期号:13 (5): e070321-e070321 被引量:1
标识
DOI:10.1136/bmjopen-2022-070321
摘要

Introduction Cold polypectomy has the advantages of simple operation, less time-consuming and fewer complications. Guidelines have recommended cold snare polypectomy (CSP) to resect small polyps sized ≤5 mm and sessile polyps sized 6–9 mm. However, evidence is scarce regarding cold resection for non-pedunculated polyps sized ≥10 mm. Cold snare endoscopic mucosal resection (CS-EMR) combining CSP and submucosal injection was designed to improve the complete resection rate and reduce adverse events. We hypothesise that CS-EMR is non-inferior to conventional hot snare endoscopic mucosal resection (HS-EMR) in the resection of 10–19 mm non-pedunculated colorectal polyps. Methods and analysis This study is a prospective, randomised, open-label, non-inferiority, single-centre trial. Outpatients scheduled to undergo a colonoscopy and present eligible polyps will be randomised to receive either CS-EMR or HS-EMR. The primary endpoint is the complete resection. Considering that HS-EMR of 10–19 mm colorectal polyps will yield a complete resection rate of at least 92% and a non-inferiority margin of −10%, a total of 232 polyps will be included (one-sided α, 2.5%; β, 20%). The analyses are intended to evaluate first non-inferiority (lower limit 95% CI greater than −10% for group difference) and then superiority (lower limit 95% CI>0%) if non-inferiority is achieved. Secondary endpoints include en-bloc resection, the occurrence of adverse events, the use of endoscopic clips, resection time and cost. Ethics and dissemination The study has been approved by the institutional review board of the Peking Union Medical College Hospital (No. K2203). All participants in the trial will provide written informed consent. The results of this trial will be published in an open-access way. Trial registration number NCT05545787 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
隐形曼青应助huangpeihao采纳,获得10
1秒前
li完成签到,获得积分10
1秒前
李健应助科研通管家采纳,获得10
1秒前
1秒前
大个应助科研通管家采纳,获得10
1秒前
ice7完成签到,获得积分10
1秒前
科研通AI2S应助科研通管家采纳,获得10
2秒前
2秒前
JamesPei应助科研通管家采纳,获得10
2秒前
共享精神应助科研通管家采纳,获得10
2秒前
Lucas应助科研通管家采纳,获得10
2秒前
RebeccaHe应助科研通管家采纳,获得20
2秒前
思源应助科研通管家采纳,获得10
2秒前
随机子应助科研通管家采纳,获得10
2秒前
8R60d8应助科研通管家采纳,获得10
2秒前
科研通AI2S应助科研通管家采纳,获得10
2秒前
3秒前
深情安青应助科研通管家采纳,获得10
3秒前
8R60d8应助科研通管家采纳,获得10
3秒前
wanci应助科研通管家采纳,获得10
3秒前
CatC完成签到,获得积分10
3秒前
ggg完成签到,获得积分10
3秒前
小蘑菇应助科研通管家采纳,获得30
3秒前
小马甲应助科研通管家采纳,获得10
3秒前
我爱酸菜鱼完成签到,获得积分10
3秒前
踏雪寻梅应助科研通管家采纳,获得10
3秒前
8R60d8应助科研通管家采纳,获得10
3秒前
款冬完成签到,获得积分10
3秒前
林林完成签到 ,获得积分10
4秒前
4秒前
小芒果完成签到,获得积分10
4秒前
韶忆秋完成签到,获得积分10
4秒前
Millennial完成签到,获得积分10
5秒前
5秒前
粗暴的海豚完成签到,获得积分10
5秒前
6秒前
专注的水壶完成签到 ,获得积分10
6秒前
香蕉觅云应助hardworkcd采纳,获得10
6秒前
peng发布了新的文献求助10
6秒前
高分求助中
Evolution 3rd edition 1500
Lire en communiste 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 700
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
the development of the right of privacy in new york 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
2-Acetyl-1-pyrroline: an important aroma component of cooked rice 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3180142
求助须知:如何正确求助?哪些是违规求助? 2830541
关于积分的说明 7978378
捐赠科研通 2492125
什么是DOI,文献DOI怎么找? 1329213
科研通“疑难数据库(出版商)”最低求助积分说明 635704
版权声明 602954